此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management (OSA_DM)

2017年11月6日 更新者:Eileen R. Chasens

OSA, Sleepiness, and Activity in Diabetes Management

Daily physical activity is important to achieve glucose control in persons with type 2 diabetes. The purpose of this study is to explore if obstructive sleep apnea and its daytime symptom, excessive sleepiness, act as barriers to physical activity. We will examine if treatment of obstructive sleep apnea with continuous positive airway pressure results in increased physical activity in persons with type 2 diabetes.

研究概览

详细说明

Obstructive sleep apnea (OSA) is a serious disorder characterized by episodic obstruction of the pharyngeal airway accompanied by cessation or reduction in airflow. Untreated OSA has a negative impact 24 hours a day, disrupting nighttime sleep and causing excessive daytime sleepiness that interferes with functioning. Recent studies suggest that OSA and type 2 diabetes (T2DM) not only co-exist but that OSA may adversely affect glucose homeostasis. While physical activity is recognized as beneficial to persons with T2DM, OSA severity or daytime sleepiness may act to hinder persons with T2DM from participating in physical activity. The primary aim of this pilot/feasibility study is to obtain preliminary data to facilitate further hypothesis development and enhance the feasibility of conducting a double blind, randomized, placebo-controlled study to examine physical activity in subjects with T2DM and OSA who are treated with CPAP compared to subjects on sham-CPAP. The secondary aims are to explore: 1) the interrelationships of OSA severity, daytime sleepiness, and physical activity on glucose variability at baseline; 2) average pre-post therapy changes in glucose variability in subjects treated with CPAP compared to subjects receiving sham-CPAP, and 3) pre to post therapy changes in weight, diet, residual sleepiness and mood in subjects treated with CPAP compared to subjects receiving sham-CPAP.

The primary endpoint of the study, physical activity, will be measured by the Bodymedia SenseWear Pro Armband® to determine activity counts. The endpoint for glucose variability will be measured by the Medtronic Continuous Glucose Monitoring System (CGMS). Adherence to CPAP will be measured by a Smart Card® inserted in subjects' CPAP machines. We will limit the sample of subjects who are randomized to CPAP or sham-CPAP to persons with an adequate sleep duration pre-treatment (> 6 hours), with moderate or severe OSA and with EDS to have a more homogenous, profoundly affected sample for this pilot study. The information that will result from the proposed study on of the effect of OSA and EDS on glucose variability has the potential to lead to the development of improved behavioral interventions in persons with diabetes. In addition, this study contains measures of diet and mood to begin to elucidate the possible effects of OSA and EDS on diabetes management.

研究类型

介入性

注册 (实际的)

23

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15261
        • University of Pittsburgh

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 65年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • T2DM (verified by primary care provider (PCP) or medication for T2DM)
  • AHI (from PSG) greater than > 15
  • A1c < 9.0%
  • Epworth Sleepiness Sca;e > 10 (Baseline Assessment)
  • Able to ambulate independently or with a cane
  • Age 40-65 years
  • BMI< 45
  • No acute medical and psychiatric illness in past 3 months
  • Self-reported sleep duration of at least 6 hours
  • No changes in medications, including diabetic medications, in last 3 months
  • Telephone access
  • Able to perform study tests (e.g., speak, read and write in English)
  • Willing to be randomized to CPAP or sham-CPAP

Exclusion Criteria:

  • Diagnosis of another sleep disorder, in addition to OSA,
  • Oxygen or Bi-level positive airway pressure required for treatment of OSA
  • An oxygen saturation <75% for >10% of the diagnostic PSG or if subject has oxygen saturation <75% for >25% of the first 4 h of the diagnostic PSG
  • Any individual in the household currently or with history of CPAP treatment
  • Type 1 or gestational diabetes
  • Prescribed insulin for treatment of type 2 diabetes
  • Regular use (> 3 times/week) of hypnotic or alerting medications
  • History of a near-miss or automobile accident due to sleepiness
  • Employed in transportation-related safety sensitive occupation such as an airline pilot, truck driver, or train engineer
  • Currently working night or rotating shifts
  • Routine consumption of alcohol as determined by >2 drinks day
  • Known allergy to medical adhesives or dermatological conditions that would preclude wearing CGMS
  • Swim or water aerobics >once a week
  • Participation in contact sports or activity that may damage CGMS device or cause injury from monitor
  • Claustrophobia that prevents wearing the CPAP mask
  • Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:1 subjects treated with CPAP
Continuous Positive Airway Pressure treatment (CPAP)
Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
假比较器:2 subjects treated with sham-CPAP
Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Physical Activity, Steps Walked
大体时间:after one-month treatment
Steps walked measured by the Bodymedia SenseWear Pro Armband®Data collected from the main study period
after one-month treatment

次要结果测量

结果测量
措施说明
大体时间
Fructosamine
大体时间:after one-month
Change in fructosamine level from baseline to one month: data from main study period
after one-month
Change in Sleep Quality
大体时间:after one month
From Pittsburgh Sleep Quality Index; scores range from 0 to 21 with higher scores worse sleep quality; data from main study period
after one month
Change in Daytime Sleepiness During Main Study Period
大体时间:after one month
Daytime Sleepiness measured by the Epworth Sleepiness Scale; measured from 0 to 24; higher scores indicate worse sleepiness
after one month
Change in Vigor-Activity During Main Study Period
大体时间:after one month
Vigor-Activity from Profiles of Mood Scale; scores range from 0 to 32 with higher scores indicating higher vigor/activity
after one month
Fatigue/Inertia
大体时间:after one month
Fatigue/Inertia from the Profile of Moods Subscale; scores range from 0 to 28; higher scores indicate more fatigue/inertia
after one month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Eileen R. Chasens, DSN、University of Pittsburgh

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年4月1日

初级完成 (实际的)

2012年4月1日

研究完成 (实际的)

2012年4月1日

研究注册日期

首次提交

2008年12月3日

首先提交符合 QC 标准的

2008年12月3日

首次发布 (估计)

2008年12月4日

研究记录更新

最后更新发布 (实际的)

2017年11月8日

上次提交的符合 QC 标准的更新

2017年11月6日

最后验证

2017年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅